Real-world outcomes after anti–IL-5/anti–IL-5Rα treatment for hypereosinophilic syndrome: Systematic literature review
Real-world anti-IL-5/anti-IL-5Rα therapy in HES is associated with fewer flares as well as reductions in bEOS counts and OCS dose, although confirmatory studies in larger populations are needed.
Authors
- S.Y. Chen
- Priya Jain (ORCID: https://orcid.org/0000-0002-2577-9351)
- Michael Stokes (ORCID: https://orcid.org/0000-0002-1822-6214)
- Jennifer Rowell (ORCID: https://orcid.org/0000-0003-1953-9770)
- Christopher Edmonds (ORCID: https://orcid.org/0000-0001-9976-8375)
- Ning Ding (ORCID: https://orcid.org/0009-0006-2548-3442)
Institutions
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (Italy) (IT)
Publication Details
- Journal
- Journal of Allergy and Clinical Immunology Global
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1016/j.jacig.2025.100608
- Primary Topic
- Eosinophilic Disorders and Syndromes
- Type
- article
- Field-Weighted Citation Impact
- 0.00